Innovation for Health - 13 February 2020
Contact Investor Forum I4H Bootcamp
Innovation for Health - Shaping the future of healthcare

Luc Sterkman

CEO, Caelus Health


14:45 - 15:35
Biotech breakthroughs

Luc Sterkman, MD (CEO) obtained his medical degree (MD) in 1988 at the Free University in Amsterdam. He has broad experience in the fields of general management, business development and R&D. From 1992-2002 he was COO and later CEO of U-Gene Research, that was successfully sold to Kendle USA (NASDAQ –KNDL). From 2002 to 2004, he worked as a Board member of the biotech company OctoPlus and from 2005 to 2010 he was General manager at the pharmaceutical company Disphar International BV (part of the Nordic Group). From 2011-2016 he worked as a COO at Newtricious, which company is focusing on innovative nutrition and functional foods. As the CEO at Caelus Health, he is since January 2016 overall responsible for building and directing the company in the next phase of growth and further expanding its pipeline of new microbiota-based products in the field of cardio-metabolic diseases.


Microbiome-based therapeutics; a new rapidly growing field
Gut microorganisms, referred to as microbiota or microbiome, represent a broad and rapidly growing basis for new products and therapies based on individual microbiota or consortia of microorganisms and /or their metabolites. These products and therapies could help prevent or treat not only gastrointestinal disorders, but also address diseases in many clinical fields including oncology, dermatology, immunology and cardiovascular disorders.

Caelus Health is a company based on technologies of the Academic Medical Centre in Amsterdam and Wageningen University. The company is dedicated to developing microbiome-based therapeutics in cardio-metabolic disorders with an initial focus on Diabetes. Caelus has secured financial support from the Johnson & Johnson Development Corporation and performs its preclinical R&D at the well-established JLABS @ BE incubator and labs on the Janssen R&D campus in Beerse. Its first product is in Phase 2 clinical trials.
Marcel Levi
University College London Hospitals
Annemarie Jorritsma
Rajiv Vaid Basaiawmoit
Aarhus University & Biosymfonix

Claudia Rijcken

Inge Huitinga
Netherlands Brain Bank
Wiro Niessen
Erasmus MC, TU Delft & Quantib
Els Beirnaert
Aelin Therapeutics
Joep Muijrers
PureTech Health
Koenraad Wiedhaup
McKinsey & Company
Esther Talboom-Kamp
Saltro Diagnostics
Elise Meijer
Antwerp Management School & Accenture Strategy
Carine van den Brink
Axon Lawyers
Tim Knotnerus
AgomAb Therapeutics
Sjaak Vink
Hans Schikan
Topsector Life Sciences & Health
Thijn Brummelkamp
Scenic Biotech
Nadine Rouleaux
Maastricht University
Dharminder Chahal
SkylineDx, Van Herk Investsments, Swanbridge

Marianne van der Steen
RegMedXB & Maastricht University

Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Silver sponsor
Programme Sponsor AI
Award sponsor
AXON Lawyers
Media sponsor
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.